Citations

Mayo Clinic

Showing 10 of 108585 citations.

The role of microRNAs in the different phases of liver regeneration
Kern, A.E. , Ortmayr, Gregor , Assinger, Alice , Kern, Anna Emilia , Assinger, Alice , Starlinger, Patrick

Expert Review of Gastroenterology & Hepatology | October 9, 2023 | Volume: 17 | Issue: 10 | Pages: 959-973

10.1080/17474124.2023.2267422 | PMID 37811642 Get It

Reply by Authors
Green, Benjamin , Flores, Ashley, Warner, Jacob, Köhler, Tobias , Trost, Landon , Helo, Sevann

Journal of Urology | October 9, 2023 | Volume: 210 | Issue: 5 | Pages: 801-802

10.1097/ju.0000000000003634.04 | PMID 37811754 Get It

Comparison of Collagenase Clostridium histolyticum to Surgery for the Management of Peyronie’s Disease: A Randomized Trial
Green, Benjamin , Flores, Ashley, Warner, Jacob, Köhler, Tobias , Trost, Landon , Helo, Sevann

Journal of Urology | October 9, 2023 | Volume: 210 | Issue: 5 | Pages: 791-802

10.1097/ju.0000000000003634 | PMID 37811752 Get It

An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals
Yabroff, K. Robin , Bradley, Cathy J. , Shih, Ya‐Chen Tina , Keating, Nancy L. , Gomez, Scarlett Lin , Banegas, Matthew P. , Sherman, Mark , Bradley, Cathy J , Ambs, Stefan , Hershman, Dawn L , Riaz, Nadeem , Yabroff, K Robin , Shih, Ya‐Chen Tina , Boehm, Amanda L. , Nogueira, Letícia , Sherman, Mark E. , Hershman, Dawn L. , Yu, James B. , Riaz, Nadeem , Stockler, Martin R. , Chen, Ronald C. , Franco, Eduardo L.

JNCI Cancer Spectrum | October 9, 2023 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/jncics/pkad063 | PMID 37806772 Get It

An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals
Yabroff, K. Robin , Boehm, Amanda L. , Bradley, Cathy J. , Shih, Ya‐Chen Tina , Keating, Nancy L. , Gomez, Scarlett Lin , Banegas, Matthew P. , Hershman, Dawn L. , Sherman, Mark , Bradley, Cathy J , Ambs, Stefan , Hershman, Dawn L , Riaz, Nadeem , Yabroff, K Robin , Shih, Ya‐Chen Tina , Nogueira, Letícia , Sherman, Mark E. , Yu, James B. , Riaz, Nadeem , Stockler, Martin R. , Chen, Ronald C. , Franco, Eduardo L.

JNCI: Journal of the National Cancer Institute | October 9, 2023 | Volume: 115 | Issue: 10 | Pages: 1115-1120

10.1093/jnci/djad177 | PMID 37806780 Get It

Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease
Pham, J. , Ghusn, Wissam , Acosta, Andrés , Loftus, Edward V. , Johnson, Amanda M. , Pham, Jonathan T , Ghusn, Wissam , Loftus, Edward V , Acosta, Andres

American Journal of Gastroenterology | October 9, 2023 | Volume: 119 | Issue: 6 | Pages: 1197-1200

10.14309/ajg.0000000000002490 | PMID 37811776 Get It

INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 ( P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
Long-Term Outcomes of Primary Hip Arthroscopy With Labral Repair for Femoroacetabular Impingement: Results at Minimum 9-Year Follow-up
Wang, Allen S. , Okoroha, Kelechi R. , Levy, Bruce A. , Lamba, Abhinav , Wang, Allen , Krych, Aaron J. , Hevesi, Mario

Orthopaedic Journal of Sports Medicine | October 9, 2023 | Volume: 11 | Issue: 10 | Pages: No page available

10.1177/23259671231204337 | PMID 37822420 Get It

Background: Hip arthroscopy continues to advance and become increasingly commonly performed. With the evolution of techniques and instrumentation, labral repair rather than debridement has emerged as the treatment of choice for labral pathology. There remains a lack of data on long-term outcomes after labral repair. Purpose: To (1) evaluate long-term patient-reported outcomes of primary hip arthroscopy with labral repair for femoroacetabular impingement, (2) report achievement rates of Patient Acceptable Symptom State (PASS) and minimal clinically important difference (MCID), and (3) investigate rates of reoperation and progression to total hip arthroplasty (THA). Study Design: Case series; Level of evidence, 4. Methods: Prospectively collected data were reviewed for patients who underwent primary hip arthroscopy with labral repair between 2010 and 2013. Patients’ medical records were reviewed for demographic characteristics, intraoperative findings, reoperation, and progression to THA. Patients were assessed pre- and postoperatively using the following scales: visual analog scale (VAS) for pain; Tegner activity scale; modified Harris Hip Score (mHHS); 12-item International Hip Outcome Tool (iHOT-12); Hip Outcome Score–Activities of Daily Living (HOS-ADL); HOS–Sport-Specific Subscale (HOS-SSS); and Non-Arthritic Hip Score. Patients were also surveyed for satisfaction, subjective improvement, and level of function. Results: A total of 32 patients (n = 24 women; n = 8 men) with a mean age of 27.7 years (range, 13.6-51 years) were evaluated for a mean of 9.4 years (range, 9-12.1 years). Patients achieved significant mean improvements in VAS pain at rest of 2 points, VAS pain with use of 1.9, mHHS of 19.9 points, iHOT-12 of 33.5 points, HOS-ADL of 17.4 points, and HOS-SSS of 29.5 points ( P≤ .015 for all). Eleven patients (34.4%) underwent reoperation and 4 (12.5%) progressed to THA during the study period. At the final follow-up, the MCID achievement rate was ≥68%, the PASS achievement rates ranged from 39% to 65%, and the mean patient satisfaction was 8.1 on a 1 to 10 scale, with 10 denoting most satisfied. Conclusion: Patients demonstrated significant postoperative improvements in pain, mHHS, iHOT-12, HOS-ADL, and HOS-SSS scores at 9 years postoperatively. The all-cause reoperation rate was 34.4%, and 12.5% of patients progressed to THA.
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
Attia, Steven , Villalobos, Víctor M. , Hindi, Nadia , Wagner, Andrew J. , Oakley, Gerard J. , Jones, Robin L. , Dickson, Mark A. , Jones, Robin L , Chmielowski, Bartosz , Peterson, Patrick M. , Ceccarelli, Matteo

Cancers | October 9, 2023 | Volume: 15 | Issue: 19 | Pages: 4871

10.3390/cancers15194871 | PMID 37835565 Get It

Gemcitabine plus docetaxel is an effective treatment regimen for advanced soft tissue sarcomas (STSs). However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Adults with unresectable locally advanced/metastatic STS, ≤2 prior lines of systemic therapy, and ECOG PS 0–1 were eligible. In Phase 2, patients were randomized 1:1 from two cohorts (O-naïve and O-pretreated) to 21-day cycles of olaratumab (20 mg/kg Cycle 1 and 15 mg/kg other cycles, Days 1 and 8), gemcitabine (900 mg/m2, Days 1 and 8), and docetaxel (75 mg/m2, Day 8). The primary objective was overall survival (OS) in the O-naïve population (α level = 0.20). Secondary endpoints included OS (O-pretreated), other efficacy parameters, patient-reported outcomes, safety, pharmacokinetics, and immunogenicity. A total of 167 and 89 patients were enrolled in the O-naïve and O-pretreated cohorts, respectively. Baseline patient characteristics were well balanced. No statistically significant difference in OS was observed between the investigational vs. control arm for either cohort (O-naïve cohort: HR = 0.95 (95% CI: 0.64−1.40), p = 0.78, median OS, 16.8 vs. 18.0 months; O-pretreated cohort: HR = 0.67 (95% CI: 0.39−1.16), p = 0.15, median OS 19.8 vs. 17.3 months). Safety was manageable across treatment arms. There was no statistically significant difference in the primary endpoint of OS between the two arms in the O-naïve population, and therefore based on hierarchical evaluation no other outcomes in this study can be considered statistically significant. No new safety signals were observed.
Scoping review and expert‐based consensus recommendations for assessment and management of psychogenic non‐epileptic (functional) seizures (PNES) in children: A report from the Pediatric Psychiatric Issues Task Force of the International League
Reilly, Colin , Jetté, Nathalie , Johnson, Emma , Kariuki, Symon M. , Meredith, Francesca, Wirrell, Elaine , Mula, Marco , Smith, Mary Lou , Walsh, Samantha , Fong, Choong Yi , Wilmshurst, Jo M. , Kerr, Mike, Johnson, Emma C , Valente, Kette , Auvin, Stéphane , Wilmshurst, Jo M , Wirrell, Elaine C , Jette, Nathalie , Valente, Kette D. , Auvin, Stéphane

Epilepsia | October 8, 2023 | Volume: 64 | Issue: 12 | Pages: 3160-3195

10.1111/epi.17768 | PMID 37804168 Get It

AbstractLimited guidance exists regarding the assessment and management of psychogenic non‐epileptic seizures (PNES) in children. Our aim was to develop consensus‐based recommendations to fill this gap. The members of the International League Against Epilepsy (ILAE) Task Force on Pediatric Psychiatric Issues conducted a scoping review adhering to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐SR) standards. This was supplemented with a Delphi process sent to pediatric PNES experts. Consensus was defined as ≥80% agreement. The systematic search identified 77 studies, the majority (55%) of which were retrospective (only one randomized clinical trial). The primary means of PNES identification was video electroencephalography (vEEG) in 84% of studies. Better outcome was associated with access to counseling/psychological intervention. Children with PNES have more frequent psychiatric disorders than controls. The Delphi resulted in 22 recommendations: Assessment—There was consensus on the importance of (1) taking a comprehensive developmental history; (2) obtaining a description of the events; (3) asking about potential stressors; (4) the need to use vEEG if available parent, self, and school reports and video recordings can contribute to a “probable” diagnosis; and (5) that invasive provocation techniques or deceit should not be employed. Management—There was consensus about the (1) need for a professional with expertise in epilepsy to remain involved for a period after PNES diagnosis; (2) provision of appropriate educational materials to the child and caregivers; and (3) that the decision on treatment modality for PNES in children should consider the child's age, cognitive ability, and family factors. Comorbidities—There was consensus that all children with PNES should be screened for mental health and neurodevelopmental difficulties. Recommendations to facilitate the assessment and management of PNES in children were developed. Future directions to fill knowledge gaps were proposed.
Biomarkers of cellular senescence and risk of death in humans
Weston, Susan A., Atkinson, Elizabeth J. , Gree, Michaela E. Mc, White, Thomas A. , Heeren, Amanda A., Rocca, Walter A. , Palmer, Allyson K. , Cummings, Steven R. , Fielding, Roger A. , St Sauver, Jennifer L , Mc Gree, Michaela E, Palmer, Allyson K , Bielinski, Suzette J. , LeBrasseur, Nathan K , Sauver, Jennifer L. St. , Mielke, Michelle M. , Olson, Janet E. , LeBrasseur, Nathan K.

Aging Cell | October 8, 2023 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/acel.14006 | PMID 37803875 Get It

AbstractA robust and heterogenous secretory phenotype is a core feature of most senescent cells. In addition to mediators of age‐related pathology, components of the senescence associated secretory phenotype (SASP) have been studied as biomarkers of senescent cell burden and, in turn, biological age. Therefore, we hypothesized that circulating concentrations of candidate senescence biomarkers, including chemokines, cytokines, matrix remodeling proteins, and growth factors, could predict mortality in older adults. We assessed associations between plasma levels of 28 SASP proteins and risk of mortality over a median follow‐up of 6.3 years in 1923 patients 65 years of age or older with zero or one chronic condition at baseline. Overall, the five senescence biomarkers most strongly associated with an increased risk of death were GDF15, RAGE, VEGFA, PARC, and MMP2, after adjusting for age, sex, race, and the presence of one chronic condition. The combination of biomarkers and clinical and demographic covariates exhibited a significantly higher c‐statistic for risk of death (0.79, 95% confidence interval (CI): 0.76–0.82) than the covariates alone (0.70, CI: 0.67–0.74) (p < 0.001). Collectively, these findings lend further support to biomarkers of cellular senescence as informative predictors of clinically important health outcomes in older adults, including death.